IVIRMA, IVI Foundation, Valencia, Spain.
Rey Juan Carlos University, Madrid, Spain.
Eur J Nutr. 2020 Oct;59(7):2841-2856. doi: 10.1007/s00394-020-02233-0. Epub 2020 May 5.
Several randomized controlled trials (RCTs) have investigated the use of probiotic/synbiotic in PCOS patients, without clarifying the real use in clinical practice. The aim of this meta-analysis was to evaluate the effectiveness of probiotics and synbiotics on metabolic, hormonal and inflammatory parameters of PCOS.
Electronic databases (MEDLINE, Scopus, EMBASE, ScienceDirect, The Cochrane Database of Systematic Reviews and ClinicalTrials.gov) were searched from their inception until May 2019. The study protocol was registered in PROSPERO with number CRD42018111534. Randomized controlled trials (RCTs) of PCOS's women undergoing therapy at least 8 weeks with probiotics or synbiotics or without therapy were included. The primary outcomes were changes in anthropometric parameters, glucose/insulin metabolism, lipid profile, sex hormones profile, inflammation markers.
587 patients were included in nine RCT. The administration of probiotic/synbiotic were associated with a significant improvement in FPG, FBI, HOMA I-R, BMI. It also modified Ferriman-Gallway, serum triglycerides, serum testosterone, hs-CRP, NO, TAC, GSH, and MDA. Subgroup analysis of the type of intervention showed that probiotics were associated with greater testosterone and FPG reduction; synbiotics administration resulted in a more pronounced decrease of the FBI. Subgroup analyses on the duration of therapy showed that, probiotic/synbiotic administration had a significantly greater effect on QUICK-I in the case of women with 12-weeks of therapy than in the 8-weeks therapy group. Nevertheless, we did not observe any significant difference was observed in terms of FBI, HOMA-IR, and FPG.
Probiotics and synbiotics seem to either an effect on/influence metabolic, hormonal and inflammatory parameters, or can influence them. Consequently, it could lead to an improvement of fertility in PCOS.
几项随机对照试验（RCT）已经研究了益生菌/合生菌在 PCOS 患者中的应用，但并未阐明其在临床实践中的实际应用。本荟萃分析旨在评估益生菌和合生菌对 PCOS 患者代谢、激素和炎症参数的有效性。
从成立到 2019 年 5 月，我们在电子数据库（MEDLINE、Scopus、EMBASE、ScienceDirect、The Cochrane Database of Systematic Reviews 和 ClinicalTrials.gov）中进行了搜索。研究方案已在 PROSPERO 中注册，编号为 CRD42018111534。纳入了接受至少 8 周益生菌或合生菌治疗或未接受治疗的 PCOS 女性的 RCT。主要结局是体重指数（BMI）、血糖/胰岛素代谢、血脂谱、性激素谱、炎症标志物的变化。
9 项 RCT 共纳入 587 名患者。益生菌/合生菌的给药与 FPG、FBI、HOMA I-R、BMI 的显著改善相关。它还改变了 Ferriman-Gallway、血清甘油三酯、血清睾酮、hs-CRP、NO、TAC、GSH 和 MDA。干预类型的亚组分析表明，益生菌与睾酮和 FPG 的降低有关；合生菌的给药导致 FBI 的降低更为明显。关于治疗持续时间的亚组分析表明，在接受 12 周治疗的女性中，益生菌/合生菌给药对 QUICK-I 的影响明显大于 8 周治疗组。然而，我们没有观察到 FBI、HOMA-IR 和 FPG 方面有任何显著差异。
益生菌和合生菌似乎对代谢、激素和炎症参数有影响/作用，或者可以影响它们。因此，它可能会改善 PCOS 的生育能力。
